Imviva is a clinical-stage biotechnology company. Our mission is to bring groundbreaking allogeneic CAR-T cell therapies to patients and enable living medicines for tomorrow’s cures.
We engineer allogeneic CAR-T cell therapies for cancers and autoimmune diseases, applying elegant immune-evasion science and an iterative design approach to overcome the challenges of performance and persistence — pushing the boundaries of cell therapy.
We are designing off-the-shelf allogeneic CAR-T cell therapies that match the power and benefit of autologous CAR-T therapies while addressing the manufacturing barriers, delays and costs that limit access today. Ready at the point of care, our approach has the unlimited potential to enable safer, more effective, cell therapies that reach more patients worldwide.
